MYND Life Sciences Inc. (MYNDF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.77 Million CAD | 37.94% |
| 2022 | 4.18 Million CAD | 52.87% |
| 2021 | 2.73 Million CAD | 5000.56% |
| 2020 | 53.68 Thousand CAD | 2838.59% |
| 2019 | 1827.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.12 Million CAD | 6.0% |
| 2024 Q3 | 6.7 Million CAD | 6.19% |
| 2024 Q2 | 6.31 Million CAD | 3.2% |
| 2023 Q1 | 4.91 Million CAD | 17.51% |
| 2023 FY | 5.77 Million CAD | 37.94% |
| 2023 Q4 | 5.77 Million CAD | -0.62% |
| 2023 Q3 | 5.81 Million CAD | 8.71% |
| 2023 Q2 | 5.34 Million CAD | 8.65% |
| 2022 Q1 | 2.95 Million CAD | 7.75% |
| 2022 FY | 4.18 Million CAD | 52.87% |
| 2022 Q4 | 4.18 Million CAD | 9.16% |
| 2022 Q3 | 3.83 Million CAD | 19.14% |
| 2022 Q2 | 3.21 Million CAD | 9.1% |
| 2021 Q1 | 585.22 Thousand CAD | 0.0% |
| 2021 FY | 2.73 Million CAD | 5000.56% |
| 2021 Q3 | 854.33 Thousand CAD | 18.76% |
| 2021 Q4 | 2.73 Million CAD | 220.53% |
| 2021 Q2 | 719.39 Thousand CAD | 22.93% |
| 2020 FY | 53.68 Thousand CAD | 2838.59% |
| 2019 FY | 1827.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ContraFect Corporation | 32.53 Million USD | 82.249% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2319.697% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3963.974% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -129.489% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.167% |
| Kadimastem Ltd | 3.5 Million USD | -64.762% |
| Zenith Capital Corp. | 27.56 Thousand USD | -20846.367% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -302.738% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -13715.412% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 68.622% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1269.816% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -50.868% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.215% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -49.937% |
| Qrons Inc. | 1.48 Million USD | -287.899% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 51.486% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -54.639% |
| Accustem Sciences Inc. | 1.07 Million USD | -435.072% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -173.027% |
| Affymax, Inc. | 8.87 Million USD | 34.904% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.136% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 38.995% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 50.971% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -20950.21% |
| Biomind Labs Inc. | 1.49 Million USD | -285.337% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 88.511% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -12.217% |
| CytoDyn Inc. | 127.89 Million USD | 95.485% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.032% |
| IMV Inc. | 37.93 Million USD | 84.776% |
| Genus plc | 485 Million USD | 98.809% |
| Halberd Corporation | 728.71 Thousand USD | -692.446% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8528.104% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 39.734% |
| LadRx Corporation | 2.2 Million USD | -162.424% |
| Marizyme, Inc. | 26.67 Million USD | 78.352% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -268.666% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.037% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -191.459% |
| Q BioMed Inc. | 8.13 Million USD | 28.996% |
| Regen BioPharma, Inc. | 5.45 Million USD | -5.81% |
| Enzolytics Inc. | 365.26 Million USD | 98.419% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Skye Bioscience, Inc. | 14.07 Million USD | 58.964% |
| SQZ Biotechnologies Company | 50.03 Million USD | 88.46% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -187.28% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 1.162% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -748.181% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 76.664% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -236.914% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -51.966% |
| NovAccess Global Inc. | 7.86 Million USD | 26.537% |
| HST Global, Inc. | 593.59 Thousand USD | -872.839% |
| SYBLEU INC | 681.41 Thousand USD | -747.46% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.541% |
| Alpha Cognition Inc. | 7.16 Million USD | 19.401% |
| AVAX Technologies, Inc. | 3.99 Million USD | -44.594% |
| Mesoblast Limited | 188.44 Million USD | 96.936% |
| MultiCell Technologies, Inc. | 1617.67 USD | -356876.639% |
| Intellipharmaceutics International Inc. | 12 Million USD | 51.913% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2771.33% |
| Neon Bloom, Inc. | 1.22 Million USD | -370.938% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 97.634% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -0.503% |
| GB Sciences, Inc. | 5.41 Million USD | -6.592% |
| argenx SE | 444.95 Million USD | 98.702% |
| Resverlogix Corp. | 67.39 Million USD | 91.432% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -588.504% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.292% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 36.136% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -57.556% |
| ONE Bio Corp. | 27.49 Million USD | 78.998% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.564% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -112.96% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -358.604% |
| Agentix Corp. | 2.51 Million USD | -130.017% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 63.692% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1142.676% |
| Cell Source, Inc. | 15.8 Million USD | 63.467% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12819.957% |
| Regen BioPharma, Inc. | 5.45 Million USD | -5.81% |
| Itoco Inc. | 1.65 Million USD | -249.315% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -181.478% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 4.535% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 47.718% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -613.989% |
| Rebus Holdings, Inc. | 5.24 Million USD | -10.162% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 5.362% |
| Mobile Lads Corp. | 1.31 Million USD | -339.643% |
| International Stem Cell Corporation | 5.27 Million USD | -9.432% |
| Bioxytran, Inc. | 3.24 Million USD | -77.711% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -822.758% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -25.071% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.914% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 74.064% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -185.116% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -5.416% |
| Neutra Corp. | 973.52 Thousand USD | -493.172% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 80.098% |
| PureTech Health plc | 125.58 Million USD | 95.402% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -53.7% |
| IXICO plc | 1.9 Million USD | -203.885% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 71.871% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.411% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Cellectis S.A. | 249.36 Million USD | 97.684% |